jetcityimage/iStock Editorial via Getty Images
The market for radioligand therapies (RLT), also known as radiopharmaceuticals, a relatively new kind of treatment, is expected to soar between now and 2030, with Novartis’ (NYSE:NVS) Pluvicto expected to account for the lion’s share as a prostate cancer
